Cai Lay Veterinary Pharmaceutical JSC (HNX:MKV)
Vietnam · Delayed Price · Currency is VND 12,800
0.00 (0.00%)
At close: Aug 12, 2026
HNX:MKV Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '19 Dec 31, 2019 |
| 153,971 | 149,787 | 107,036 | 110,906 | 119,634 | 102,410 | |
Revenue Growth | 25.44% | 39.94% | -3.49% | -7.30% | 16.82% | -23.90% |
Cost of Revenue | 100,588 | 97,108 | 71,100 | 78,674 | 86,605 | 80,112 |
Gross Profit | 53,384 | 52,679 | 35,937 | 32,232 | 33,029 | 22,298 |
Selling, General & Admin | 32,383 | 28,133 | 23,877 | 21,539 | 21,086 | 14,185 |
Operating Expenses | 32,383 | 28,133 | 23,877 | 21,539 | 21,086 | 14,185 |
Operating Income | 21,001 | 24,545 | 12,060 | 10,693 | 11,942 | 8,113 |
Interest Expense | - | - | -38.53 | -481.41 | -1,182 | -3,891 |
Interest & Investment Income | 1,953 | 886.88 | 428.6 | 285.51 | 247.49 | 1.04 |
Currency Exchange Gain (Loss) | -7.27 | -7.27 | -8.44 | 9 | - | - |
Other Non Operating Income (Expenses) | -4,337 | -4,311 | -3,245 | -2,754 | -3,507 | -1,721 |
Pretax Income | 18,610 | 21,114 | 9,197 | 7,752 | 7,502 | 2,502 |
Income Tax Expense | 3,728 | 4,224 | 1,872 | 1,550 | 1,598 | 735.25 |
Net Income | 14,881 | 16,890 | 7,324 | 6,201 | 5,904 | 1,767 |
Net Income to Common | 14,881 | 16,890 | 7,324 | 6,201 | 5,904 | 1,767 |
Net Income Growth | 137.31% | 130.61% | 18.11% | 5.04% | 234.10% | - |
Shares Outstanding (Basic) | 5 | 5 | 5 | 5 | 5 | - |
Shares Outstanding (Diluted) | 5 | 5 | 5 | 5 | 5 | - |
Shares Change | -0.09% | - | - | 0.02% | - | - |
EPS (Basic) | 2978.32 | 3378.05 | 1464.86 | 1240.29 | 1181.00 | - |
EPS (Diluted) | 2978.26 | 3378.00 | 1464.86 | 1240.00 | 1181.00 | - |
EPS Growth | 137.53% | 130.60% | 18.13% | 5.00% | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '19 Dec 31, 2019 |
Free Cash Flow | 28,793 | 19,573 | 5,597 | 24,406 | 7,031 | 21,909 |
Free Cash Flow Per Share | 5762.60 | 3914.70 | 1119.37 | 4881.24 | 1406.48 | - |
Gross Margin | 34.67% | 35.17% | 33.57% | 29.06% | 27.61% | 21.77% |
Operating Margin | 13.64% | 16.39% | 11.27% | 9.64% | 9.98% | 7.92% |
Profit Margin | 9.66% | 11.28% | 6.84% | 5.59% | 4.93% | 1.73% |
Free Cash Flow Margin | 18.70% | 13.07% | 5.23% | 22.01% | 5.88% | 21.39% |
EBITDA | 25,229 | 28,723 | 16,290 | 17,863 | 19,759 | 16,660 |
EBITDA Margin | 16.38% | 19.18% | 15.22% | 16.11% | 16.52% | 16.27% |
D&A For EBITDA | 4,228 | 4,178 | 4,231 | 7,171 | 7,816 | 8,546 |
EBIT | 21,001 | 24,545 | 12,060 | 10,693 | 11,942 | 8,113 |
EBIT Margin | 13.64% | 16.39% | 11.27% | 9.64% | 9.98% | 7.92% |
Effective Tax Rate | 20.04% | 20.00% | 20.36% | 20.00% | 21.30% | 29.38% |
Revenue as Reported | 153,971 | 149,787 | 107,036 | 110,906 | 119,634 | 102,410 |